Enveric Biosciences (ENVB) announced that it has received a notice of allowance from the United States Patent and Trademark Office for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENVB:
- Enveric Biosciences receives notice of allowance from USPTO for EVM401
- Psychedelic: Clearmind reports results from first cohort in AUD trial
- Enveric Biosciences Regains Nasdaq Compliance
- Enveric Biosciences trading halted, news pending
- Upcoming Stock Splits This Week (October 27 to October 31) – Stay Invested